Trends in FDA Transporter‐Based Post‐Marketing Requirements and Commitments Over the Last Decade

Characterizing interactions between new molecular entities (NMEs) and drug transporters is a critical element of drug development that helps in assessing potential transporter‐based drug–drug interactions (DDIs). However, not all NME new drug applications (NDAs) include a full characterization of NMEs transporter‐based DDIs, which necessitates the issuance of post‐marketing requirement (PMR)/post‐marketing commitment (PMC) by the US Food and Drug Administration (FDA) to characterize these potential interactions. The objective of this analysis is to identify trends in transporter‐based PMRs/PMCs issued by the FDA between 2012 and 2021. A decrease in the number of transporter‐based PMRs/PMCs was observed from 2012 to 2016 and an increasing trend in the number of PMRs/PMCs was observed after 2017. The majority of these transporter‐based PMRs/PMCs requested clinical evaluation (48%), some requested in vitro assessment (38%), and 2.5% requested modeling and simulation assessment. Most of the PMRs/PMCs requested evaluation of NMEs as perpetrator with the efflux transporters, P‐gp and/or BCRP (53%). Forty‐eight percent of the PMRs/PMCs were fulfilled with 67% resulted in labeling updates. On average, 2.5 years were needed for the information related to PMRs/PMCs to show in NMEs labeling. In conclusion, this analysis highlights the increased emphasis from the FDA on proper characterization of transporter‐based DDI and call for the need of early characterization of NMEs‐transporters interaction before initial NDA approval.